Decarboxylase

Carboxy-lyases, also known as decarboxylases, are carbon–carbon lyases that add or remove a carboxyl group from organic compounds. These enzymes catalyze the decarboxylation of amino acids, beta-keto acids and alpha-keto acids.

Cat. No.	Product name	CAS No.	Purity
T17166	Tritoqualine	14504-73-5	98%
Tritoqualine is used as an inhibitor of histidine decarboxylase.
T7454	4-Bromo-3-hydroxybenzoic acid	14348-38-0	97.72%
4-bromo-3-hydroxybenzoic acid is a potent inhibitor of the enzyme histidine decarboxylase.
T6795	Carbidopa	28860-95-9	98.01%
Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.
T2148	Carbidopa monohydrate	38821-49-7	99.29%
Carbidopa Hydrate is an inhibitor of DOPA decarboxylase, preventing the conversion of levodopa to dopamine.
T2593	Eflornithine hydrochloride hydrate	96020-91-6	99.64%
Eflornithine hydrochloride is a specific, irreversible inhibitor of ornithine decarboxylase.
T0737	L-Ornithine	70-26-8	99.73%
L-ornithine has an anti-fatigue function in facilitating the excretion of ammonia and increasing the efficiency of energy consumption.

Cat. No.

Product name

CAS No.

Purity

Chemical Structure

T17166

Tritoqualine

14504-73-5

98%

Tritoqualine is used as an inhibitor of histidine decarboxylase.

T7454

4-Bromo-3-hydroxybenzoic acid

14348-38-0

97.72%

4-bromo-3-hydroxybenzoic acid is a potent inhibitor of the enzyme histidine decarboxylase.

T6795

Carbidopa

28860-95-9

98.01%

Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.

T2148

Carbidopa monohydrate

38821-49-7

99.29%